TNSN98154A1 - Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant - Google Patents

Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant

Info

Publication number
TNSN98154A1
TNSN98154A1 TNTNSN98154A TNSN98154A TNSN98154A1 TN SN98154 A1 TNSN98154 A1 TN SN98154A1 TN TNSN98154 A TNTNSN98154 A TN TNSN98154A TN SN98154 A TNSN98154 A TN SN98154A TN SN98154 A1 TNSN98154 A1 TN SN98154A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical compositions
compositions containing
novel
aminopyridine derivatives
aminopyridine
Prior art date
Application number
TNTNSN98154A
Other languages
English (en)
Inventor
Adams Lowe John Iii
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN98154A1 publication Critical patent/TNSN98154A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

L'INVENTION CONCERNE DES DERIVES DE 2- AMINOPYRIDINE DE FORMULE.DANS LAQUELLE A REPRESENTE UN NOYEAU, X REPRESENTE L'OXYGENE OU UNE LIAISON ET R1 ET R2 SONT CHOISIS ENTRE DIVERS RADICAUX. ELLE CONCERNE EGALEMENT DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET UN PROCEDE DE PREPARATION. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS, COMME INHIBITEUTRS DE L'OXYDE NITRIQUE-SYNTHETASE (NOS), DANS LE TRAITEMENT ET LA PREVENTION DE TROUBLES DU SYSTEME NERVEUX CENTRAL ET D'AUTRES AFFECTIONS
TNTNSN98154A 1997-08-27 1998-08-26 Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant TNSN98154A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5709497P 1997-08-27 1997-08-27

Publications (1)

Publication Number Publication Date
TNSN98154A1 true TNSN98154A1 (fr) 2005-03-15

Family

ID=22008463

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98154A TNSN98154A1 (fr) 1997-08-27 1998-08-26 Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant

Country Status (40)

Country Link
EP (1) EP1007520B1 (fr)
JP (1) JP3411271B2 (fr)
KR (1) KR100367277B1 (fr)
CN (1) CN1268133A (fr)
AP (1) AP1213A (fr)
AR (1) AR014110A1 (fr)
AT (1) ATE248161T1 (fr)
AU (1) AU8458898A (fr)
BG (1) BG104138A (fr)
BR (1) BR9811555A (fr)
CA (1) CA2296313C (fr)
CO (1) CO4970728A1 (fr)
DE (1) DE69817584T2 (fr)
DK (1) DK1007520T3 (fr)
DZ (1) DZ2594A1 (fr)
EA (1) EA003839B1 (fr)
ES (1) ES2203976T3 (fr)
GT (1) GT199800128A (fr)
HN (1) HN1998000118A (fr)
HR (1) HRP980470A2 (fr)
HU (1) HUP0003700A3 (fr)
ID (1) ID24087A (fr)
IL (1) IL133958A0 (fr)
IS (1) IS5344A (fr)
MA (1) MA26537A1 (fr)
NO (1) NO20000958L (fr)
NZ (1) NZ502281A (fr)
OA (1) OA11288A (fr)
PA (1) PA8456901A1 (fr)
PE (1) PE106599A1 (fr)
PL (1) PL338987A1 (fr)
PT (1) PT1007520E (fr)
SK (1) SK1402000A3 (fr)
TN (1) TNSN98154A1 (fr)
TR (1) TR200000535T2 (fr)
UA (1) UA55461C2 (fr)
UY (1) UY25158A1 (fr)
WO (1) WO1999010339A1 (fr)
YU (1) YU10900A (fr)
ZA (1) ZA987726B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
NZ508101A (en) 1998-04-10 2002-12-20 Japan Tobacco Inc Amidine compounds useful as factor Xa inhibitors and as anticoagulants
ID27027A (id) * 1998-06-03 2001-02-22 Pfizer Prod Inc 2-aminopiridin yang mengandung substituen cincin lebur
WO2000009130A2 (fr) * 1998-08-11 2000-02-24 Pfizer Products Inc. Nouvelles utilisations pharmaceutiques pour les inhibiteurs de nos
KR20010114213A (ko) 1999-02-25 2001-12-31 실버스타인 아써 에이. 접합 고리 치환기를 함유한 2-아미노피리딘
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004149D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
AU2001283393B2 (en) * 2000-08-16 2005-09-22 Pharmacia & Upjohn Company Compounds for the treatment of addictive disorders
CN100356917C (zh) 2001-05-15 2007-12-26 霍夫曼-拉罗奇有限公司 用作糖尿病治疗中的PPAR－α和PPAR－γ激活剂的羧酸取代的噁唑衍生物
SE0102640D0 (sv) 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10159922A1 (de) * 2001-12-06 2003-06-26 Gruenenthal Gmbh Substituierte 2-Pyrrolidin-2-yl-1H-indol-Derivate
KR100621294B1 (ko) 2002-07-03 2006-09-06 에프. 호프만-라 로슈 아게 옥사졸 유도체 및 이의 인슐린 증감제로서의 용도
NZ538058A (en) * 2002-08-14 2006-11-30 Neurosearch As Quinuclidine derivatives and their use for treating disorders related to CNS and PNS
ATE483699T1 (de) 2002-08-30 2010-10-15 Hoffmann La Roche Neue 2-arylthiazolverbindungen als ppar-alpha und gamma agonisten
EP1539746B1 (fr) 2002-09-12 2006-11-15 F. Hoffmann-La Roche Ag Composes d'acide 1h-indol-5-propionique en tant qu'agonistes de ppar utiles dans le traitement du diabete
US20040092741A1 (en) * 2002-11-08 2004-05-13 Pfizer Inc Substituted pyridines via boronic acid coupling
MXPA05005445A (es) 2002-11-25 2005-08-26 Hoffmann La Roche Derivados de indolilo.
CA2551486A1 (fr) * 2003-12-22 2006-06-22 Abbott Laboratories Derives polycycliques de quinuclidine substitues par un bicycloheterocycle condense
US7160876B2 (en) 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20080194547A1 (en) * 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
TW200924772A (en) * 2007-08-27 2009-06-16 Kalypsys Inc Heterobicyclic-substituted quinolones useful as nitric oxide synthase inhibitors
WO2009029617A1 (fr) * 2007-08-27 2009-03-05 Kalypsys, Inc. Quinolones substituées par diarylamine utiles comme inhibiteurs de l'oxyde nitrique synthase inductible.
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
DE102008054141A1 (de) 2008-10-31 2010-05-06 Merck Patent Gmbh Neue Materialien für organische Elektrolumineszenzvorrichtungen
DE102009033371A1 (de) 2009-07-16 2011-05-12 Merck Patent Gmbh Materialien für elektronische Vorrichtungen
US9120750B2 (en) 2013-03-07 2015-09-01 Northwestern University 2-Aminopyridine-based selective neuronal nitric oxide synthase inhibitors
CN104725249B (zh) * 2013-12-20 2019-02-12 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
WO2016073623A2 (fr) 2014-11-04 2016-05-12 Northwestern University Inhibiteurs d'oxyde nitrique synthase d'origine bactérienne et mammalienne
CN106478376A (zh) * 2016-10-08 2017-03-08 贵州大学 一种4‑氟萘‑1‑醇的制备工艺
CN114560779A (zh) * 2022-01-25 2022-05-31 杭州华东医药集团浙江华义制药有限公司 一种米拉贝隆关键中间体的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT400845B (de) * 1993-12-06 1996-03-25 Chem Pharm Forsch Gmbh Neue thienothiazinderivate, ein verfahren zu ihrer herstellung und ihre verwendung
WO1996018616A1 (fr) * 1994-12-12 1996-06-20 Merck & Co., Inc. 2-aminopyridines substituees utilisees comme inhibiteurs de synthase d'oxyde d'azote
JPH08311028A (ja) * 1995-05-17 1996-11-26 Japan Tobacco Inc ２−アミノピリジン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤
JPH09132529A (ja) * 1995-11-09 1997-05-20 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤
PT891332E (pt) * 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina

Also Published As

Publication number Publication date
KR100367277B1 (ko) 2003-01-09
IS5344A (is) 2000-01-14
ES2203976T3 (es) 2004-04-16
NZ502281A (en) 2002-09-27
YU10900A (sh) 2002-12-10
PT1007520E (pt) 2003-12-31
DE69817584D1 (de) 2003-10-02
DK1007520T3 (da) 2003-11-24
CO4970728A1 (es) 2000-11-07
PL338987A1 (en) 2000-12-04
PE106599A1 (es) 1999-11-02
EA200000171A1 (ru) 2000-10-30
NO20000958D0 (no) 2000-02-25
PA8456901A1 (es) 2000-05-24
TR200000535T2 (tr) 2000-11-21
OA11288A (en) 2003-08-22
CN1268133A (zh) 2000-09-27
BR9811555A (pt) 2000-09-12
AU8458898A (en) 1999-03-16
KR20010022433A (ko) 2001-03-15
HUP0003700A2 (hu) 2001-10-28
GT199800128A (es) 2000-02-01
HRP980470A2 (en) 1999-06-30
ATE248161T1 (de) 2003-09-15
BG104138A (en) 2000-11-30
EP1007520A1 (fr) 2000-06-14
JP3411271B2 (ja) 2003-05-26
EA003839B1 (ru) 2003-10-30
ID24087A (id) 2000-07-06
DZ2594A1 (fr) 2003-02-22
UY25158A1 (es) 2000-12-29
EP1007520B1 (fr) 2003-08-27
CA2296313C (fr) 2004-11-02
HN1998000118A (es) 1999-02-09
AR014110A1 (es) 2001-02-07
CA2296313A1 (fr) 1999-03-04
JP2001514176A (ja) 2001-09-11
SK1402000A3 (en) 2000-07-11
NO20000958L (no) 2000-04-14
IL133958A0 (en) 2001-04-30
ZA987726B (en) 2000-02-28
AP9801330A0 (en) 1998-09-30
WO1999010339A1 (fr) 1999-03-04
AP1213A (en) 2003-10-07
DE69817584T2 (de) 2004-04-01
HUP0003700A3 (en) 2002-09-30
UA55461C2 (uk) 2003-04-15
MA26537A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
TNSN98154A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant
TNSN97055A1 (fr) Derives de 6-phenylpyridyl -2- amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN98024A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l&#39;adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98053A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant.
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d&#39;isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN98112A1 (fr) Composes dipeptidiques
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN96172A1 (fr) Composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98216A1 (fr) Derives d&#39;acide hydrauxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
ATE202076T1 (de) Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
TNSN98045A1 (fr) Derives de nicotinamide nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98066A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98036A1 (fr) Derives d&#39;acide hexanoique nouveaux